Daniel Patrick O'Day
At a glance: Daniel Patrick O'Day is CEO, Chair at Gilead Sciences (GILD). Their latest SEC Form 4, filed Nov 6, 2026, reported a sale of $18.0M. On file: 0 purchase lines ($0) and 36 sale lines ($77.5M).
Disclosed holdings: about $92.2M of GILD stock: 551,683 shares reported on their latest Form 4 (filed Nov 6, 2026), valued at the Nov 19, 2026 close of $167.13. This counts only GILD shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
CEO, Chair at Gilead Sciences, Inc. (GILD)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Daniel Patrick O'Day's InsiderPrint
36 trades from SEC Form 4 filings, 2025 to 2026, drawn as one fingerprint.
Reading this print: Almost only sells, trading about 35 times a year, typically $861K a trade; most sales are on a pre-planned 10b5-1 schedule.
- Bump outward: a purchase (0)
- Dent inward: a sale (36)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Insiders with a similar print
- Mark D. PapermasterCTO · AMD · 100% match
- Sheldon Richard BentleyFounder · CSAI · 100% match
- Alclear Investments, LLCSee Remarks · YOU · 100% match
- Benjamin SilbermannDirector · PINS · 100% match
- Steven M. QuirkChief Brokerage Officer · HOOD · 100% match
Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Nov 6SEC | GILDGilead Sciences, Inc. | Sell Plan | 102,619551,683 held (−16%) | $175.16 | $18.0M | -4.6% |
| Nov 6SEC | GILDGilead Sciences, Inc. | Sell Plan | 9,810551,683 held (−2%) | $175.17 | $1.7M | -4.6% |
| Nov 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 15,881566,683 held (−3%) | $175.25 | $2.8M | -4.6% |
| Nov 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 1,600565,083 held (−0%) | $167.40 | $268K | -0.2% |
| Nov 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 1,700563,383 held (−0%) | $168.10 | $286K | -0.6% |
| Nov 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 1,904561,479 held (−0%) | $169.27 | $322K | -1.3% |
| Nov 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 7,796553,683 held (−1%) | $170.35 | $1.3M | -1.9% |
| Nov 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 2,000551,683 held (−0%) | $171.06 | $342K | -2.3% |
| Oct 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 12,000569,683 held (−2%) | $147.72 | $1.8M | +13.1% |
| Oct 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 3,000566,683 held (−1%) | $148.63 | $446K | +12.5% |
| Sep 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 1,600590,533 held (−0%) | $147.51 | $236K | +13.3% |
| Sep 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 7,992582,541 held (−1%) | $148.36 | $1.2M | +12.7% |
| Sep 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 5,408577,133 held (−1%) | $149.38 | $808K | +11.9% |
| Aug 4SEC | GILDGilead Sciences, Inc. | Sell Plan | 6,700600,433 held (−1%) | $129.66 | $869K | +28.9% |
| Aug 4SEC | GILDGilead Sciences, Inc. | Sell Plan | 7,700592,733 held (−1%) | $130.80 | $1.0M | +27.8% |
| Aug 4SEC | GILDGilead Sciences, Inc. | Sell Plan | 600592,133 held (−0%) | $131.34 | $79K | +27.3% |
| Jul 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 11,900610,233 held (−2%) | $126.09 | $1.5M | +32.6% |
| Jul 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 3,100607,133 held (−1%) | $127.08 | $394K | +31.5% |
| Jun 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 10,900621,667 held (−2%) | $131.10 | $1.4M | +27.5% |
| Jun 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 3,062618,605 held (−0%) | $132.22 | $405K | +26.4% |
| Jun 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 1,038617,567 held (−0%) | $132.97 | $138K | +25.7% |
| Apr 29SEC | GILDGilead Sciences, Inc. | Sell Plan | 6,950635,617 held (−1%) | $128.79 | $895K | +29.8% |
| Apr 29SEC | GILDGilead Sciences, Inc. | Sell Plan | 3,050632,567 held (−0%) | $130.01 | $397K | +28.6% |
| Mar 30SEC | GILDGilead Sciences, Inc. | Sell Plan | 10,000642,567 held (−2%) | $136.82 | $1.4M | +22.2% |
| Mar 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 3,481648,827 held (−1%) | $144.04 | $501K | +16.0% |
| Mar 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 6,419642,408 held (−1%) | $145.18 | $932K | +15.1% |
| Mar 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 100642,308 held (−0%) | $145.71 | $15K | +14.7% |
| Feb 6SEC | GILDGilead Sciences, Inc. | Sell Plan | 115,640613,912 held (−16%) | $150.00 | $17.3M | +11.4% |
| Jan 29SEC | GILDGilead Sciences, Inc. | Sell Plan | 5,032561,666 held (−1%) | $139.54 | $702K | +19.8% |
| Jan 29SEC | GILDGilead Sciences, Inc. | Sell Plan | 4,968556,698 held (−1%) | $140.24 | $697K | +19.2% |
| Jan 26SEC | GILDGilead Sciences, Inc. | Sell Plan | 115,640566,698 held (−17%) | $135.00 | $15.6M | +23.8% |
| Dec 30SEC | GILDGilead Sciences, Inc. | Sell Plan | 10,000566,698 held (−2%) | $124.83 | $1.2M | +33.9% |
| Dec 1SEC | GILDGilead Sciences, Inc. | Sell Plan | 3,212577,991 held (−1%) | $125.91 | $404K | +32.7% |
| Dec 1SEC | GILDGilead Sciences, Inc. | Sell Plan | 6,788571,203 held (−1%) | $126.84 | $861K | +31.8% |
| Oct 29SEC | GILDGilead Sciences, Inc. | Sell Plan | 7,978583,225 held (−1%) | $119.54 | $954K | +39.8% |
| Oct 29SEC | GILDGilead Sciences, Inc. | Sell Plan | 2,022581,203 held (−0%) | $118.82 | $240K | +40.7% |
- Sell
CEO, Chair Daniel Patrick O'day sold $18.0M of GILD at $175.16 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, Chair Daniel Patrick O'day sold $1.7M of GILD at $175.17 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, Chair Daniel Patrick O'day sold $2.8M of GILD at $175.25 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, Chair Daniel Patrick O'day sold $268K of GILD at $167.40 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, Chair Daniel Patrick O'day sold $286K of GILD at $168.10 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, Chair Daniel Patrick O'day sold $322K of GILD at $169.27 — pre-scheduled 10b5-1 plan sale.
Follow Daniel Patrick O'Day
Get one email when Daniel Patrick O'Day files a new purchase or sale. Free.
At most one email a day about Daniel Patrick O'Day, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.